LRI Commends GSK as Leader in Sharing Clinical Data

The Lupus Research Institute commends GlaxoSmithKline (GSK) for announcing their plans to share all their clinical trial information with the scientific community. For lupus patients, it will give scientists access to a breadth of data to learn more about the results of clinical trials testing the safety and effectiveness of the first treatment for lupus in 50 years, Benlysta.

As noted by many industry commentators, this represents a leadership step in transparency among the pharmaceutical industry.